CLRB
Price
$3.02
Change
-$0.08 (-2.57%)
Updated
Apr 24, 1:34 PM EST
12 days until earnings call
MBRX
Price
$4.42
Change
-$0.18 (-3.91%)
Updated
Apr 24, 2:38 PM EST
15 days until earnings call
Ad is loading...

CLRB vs MBRX ᐉ Comparison: Which is Better to Invest?

Header iconCLRB vs MBRX Comparison
Open Charts CLRB vs MBRXBanner chart's image
Cellectar Biosciences
Price$3.02
Change-$0.08 (-2.57%)
Volume$6.3K
CapitalizationN/A
Moleculin Biotech
Price$4.42
Change-$0.18 (-3.91%)
Volume$400
CapitalizationN/A
View a ticker or compare two or three
CLRB vs MBRX Comparison Chart

Loading...

CLRBDaily Signal changed days agoGain/Loss if shorted
 
Show more...
MBRXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CLRB vs. MBRX commentary
Apr 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLRB is a StrongSell and MBRX is a Hold.

COMPARISON
Comparison
Apr 24, 2024
Stock price -- (CLRB: $3.11 vs. MBRX: $4.60)
Brand notoriety: CLRB and MBRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLRB: 84% vs. MBRX: 17%
Market capitalization -- CLRB: $100.33M vs. MBRX: $10.25M
CLRB [@Biotechnology] is valued at $100.33M. MBRX’s [@Biotechnology] market capitalization is $10.25M. The market cap for tickers in the [@Biotechnology] industry ranges from $557.83B to $0. The average market capitalization across the [@Biotechnology] industry is $2.55B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLRB’s FA Score shows that 0 FA rating(s) are green whileMBRX’s FA Score has 1 green FA rating(s).

  • CLRB’s FA Score: 0 green, 5 red.
  • MBRX’s FA Score: 1 green, 4 red.
According to our system of comparison, CLRB is a better buy in the long-term than MBRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLRB’s TA Score shows that 3 TA indicator(s) are bullish while MBRX’s TA Score has 5 bullish TA indicator(s).

  • CLRB’s TA Score: 3 bullish, 6 bearish.
  • MBRX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, MBRX is a better buy in the short-term than CLRB.

Price Growth

CLRB (@Biotechnology) experienced а -6.04% price change this week, while MBRX (@Biotechnology) price change was +7.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.45%. For the same industry, the average monthly price growth was -3.10%, and the average quarterly price growth was +1265.15%.

Reported Earning Dates

CLRB is expected to report earnings on Aug 12, 2024.

MBRX is expected to report earnings on May 09, 2024.

Industries' Descriptions

@Biotechnology (+0.45% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for CLRB with price predictions.
OPEN
A.I.dvisor published
a Summary for MBRX with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
CLRB($100M) has a higher market cap than MBRX($10.2M). CLRB YTD gains are higher at: 12.274 vs. MBRX (-64.275).
CLRBMBRXCLRB / MBRX
Capitalization100M10.2M980%
EBITDAN/AN/A-
Gain YTD12.274-64.275-19%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/A574K-
FUNDAMENTALS RATINGS
CLRB vs MBRX: Fundamental Ratings
CLRB
MBRX
OUTLOOK RATING
1..100
5950
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
12
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
4892
P/E GROWTH RATING
1..100
75100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MBRX's Valuation (12) in the Pharmaceuticals Major industry is somewhat better than the same rating for CLRB (64) in the Biotechnology industry. This means that MBRX’s stock grew somewhat faster than CLRB’s over the last 12 months.

MBRX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CLRB (100) in the Biotechnology industry. This means that MBRX’s stock grew similarly to CLRB’s over the last 12 months.

MBRX's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as CLRB (100) in the Biotechnology industry. This means that MBRX’s stock grew similarly to CLRB’s over the last 12 months.

CLRB's Price Growth Rating (48) in the Biotechnology industry is somewhat better than the same rating for MBRX (92) in the Pharmaceuticals Major industry. This means that CLRB’s stock grew somewhat faster than MBRX’s over the last 12 months.

CLRB's P/E Growth Rating (75) in the Biotechnology industry is in the same range as MBRX (100) in the Pharmaceuticals Major industry. This means that CLRB’s stock grew similarly to MBRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLRBMBRX
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
75%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
62%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
N/A
Bullish Trend 6 days ago
74%
Declines
ODDS (%)
Bearish Trend 6 days ago
86%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 3 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
CLRBDaily Signal changed days agoGain/Loss if shorted
 
Show more...
MBRXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IMCR57.311.49
+2.67%
Immunocore Holdings plc
BSY54.421.22
+2.29%
Bentley Systems
AC32.720.29
+0.89%
Associated Capital Group
INOD5.740.05
+0.88%
Innodata
ASST0.40-0.01
-2.24%
Asset Entities

CLRB and

Correlation & Price change

A.I.dvisor tells us that CLRB and VTGN have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLRB and VTGN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLRB
1D Price
Change %
CLRB100%
-2.51%
VTGN - CLRB
33%
Poorly correlated
+1.05%
ORMP - CLRB
31%
Poorly correlated
+0.86%
AXON - CLRB
31%
Poorly correlated
+2.64%
FATE - CLRB
30%
Poorly correlated
-5.02%
MDGL - CLRB
28%
Poorly correlated
+2.29%
More

MBRX and

Correlation & Price change

A.I.dvisor tells us that MBRX and AVRO have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MBRX and AVRO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MBRX
1D Price
Change %
MBRX100%
+6.98%
AVRO - MBRX
32%
Poorly correlated
+0.83%
AMRN - MBRX
32%
Poorly correlated
+2.03%
AXON - MBRX
29%
Poorly correlated
+2.64%
VKTX - MBRX
29%
Poorly correlated
+1.69%
NTBL - MBRX
28%
Poorly correlated
+3.16%
More